Diagnostic Approach and Management of Proctitis

Initial Evaluation and Testing

The Centers for Disease Control and Prevention recommends evaluating patients with proctitis for symptoms including anorectal pain, tenesmus, rectal discharge, rectal bleeding, constipation, and diarrhea 1, 2
A detailed sexual history should be obtained, particularly regarding receptive anal intercourse, which is a major risk factor for sexually transmitted proctitis 1, 3
Patients with proctitis should be assessed for HIV status, as herpes proctitis can be especially severe in HIV-infected individuals 1

Anoscopy should be performed to visualize the rectal mucosa and collect specimens for testing, including Gram-stained smear of anorectal exudate to examine for polymorphonuclear leukocytes 2
Samples should be collected for specific pathogen testing, including HSV (PCR or culture), N. gonorrhoeae (NAAT or culture), C. trachomatis (NAAT), and T. pallidum (darkfield if available and serologic testing) 2
If C. trachomatis test is positive, a molecular PCR test for LGV should be performed to confirm LGV diagnosis 2

Presumptive therapy should be initiated for patients with acute proctitis who recently practiced receptive anal intercourse and have anorectal exudate or polymorphonuclear leukocytes on Gram stain, while awaiting test results 2
The recommended treatment includes ceftriaxone 250 mg IM in a single dose plus doxycycline 100 mg orally twice a day for 7 days 2
Partners who had sexual contact with persons treated for gonorrhea, chlamydia, or LGV within 60 days before symptom onset should be evaluated, tested, and treated presumptively 2, 4

Patients with proctitis associated with gonorrhea or chlamydia should be retested for the respective pathogen 3 months after treatment 2, 4
Patients should be monitored for resolution of symptoms, including rectal pain, discharge, bleeding, and tenesmus 4
For persistent symptoms after treatment, patients should be evaluated for possible reinfection or treatment failure 4

In adults with acute infectious proctitis, doxycycline 100 mg twice daily provides antimicrobial activity against Chlamydia trachomatis (including LGV strains) as well as Mycoplasma and Ureaplasma species, complementing ceftriaxone’s gonococcal coverage. 5

For patients unable to receive ceftriaxone (e.g., drug shortage or cephalosporin allergy), a single oral dose of cefixime 400 mg combined with azithromycin 1 g offers comparable gonorrhea coverage. 6
In cases of confirmed cephalosporin allergy, a single intramuscular dose of gentamicin 240 mg together with azithromycin 2 g orally provides an effective alternative regimen. 6

When patients present with severe symptoms, fever, or systemic illness, a single intravenous dose of ceftriaxone 1 g is considered equally effective as the standard intramuscular dose and may improve tolerability by avoiding injection discomfort. 6